SBRT then Pembrolizumab: Well tolerated in met tumours

Treatment with the immune checkpoint inhibitor pembrolizumab after administration of multisite stereotactic body radiation therapy was well tolerated in an early-phase trial of patients with metastatic solid tumours. Some patients also experienced responses to the treatment.
Cancer Network